Zaloguj się

Gotowe bibliografie tematyczne / Hydergine / Artykuły w czasopismach

Artykuły w czasopismach na temat „Hydergine”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Hydergine.

Autor: Grafiati

Data publikacji: 26 lipca 2024

Data aktualizacji: 28 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Hydergine”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Nussenblatt, RobertB, HowardA Austin, AlanG Palestine i HarryG Preuss. "HYDERGINE AND CYCLOSPORIN NEPHROTOXICITY". Lancet 327, nr 8491 (maj 1986): 1220–21. http://dx.doi.org/10.1016/s0140-6736(86)91209-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

TAMURA, TAKASHI, TAIICHI SATOH, HISANORI MINAKAMI i TARO TAMADA. "Effect of Hydergine in Hyperprolactinemia". Journal of Clinical Endocrinology & Metabolism 69, nr 2 (sierpień 1989): 470–74. http://dx.doi.org/10.1210/jcem-69-2-470.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Guida, Charles V. "Review: Hydergine is effective for dementia". ACP Journal Club 122, nr 1 (1.01.1995): 17. http://dx.doi.org/10.7326/acpjc-1995-122-1-017.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Kho, T. L., R. Kengen, K. M. L. Leunissen, J. Teule i J. P. Van Hooff. "HYDERGINE AND REVERSIBILITY OF CYCLOSPORIN NEPHROTOXICITY". Lancet 328, nr 8503 (sierpień 1986): 394–95. http://dx.doi.org/10.1016/s0140-6736(86)90077-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

&NA;. "Hydergine-LC appears ineffective in Alzheimer's disease". Inpharma Weekly &NA;, nr 751 (sierpień 1990): 9–10. http://dx.doi.org/10.2165/00128413-199007510-00027.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Romero, R., A. Felip, J. M. Llibre, J. Bonet i A. Caralps. "Co-Dergocrine Mesylate (Hydergine) and Hypertensive Emergencies". Nephron 51, nr 1 (1989): 127–28. http://dx.doi.org/10.1159/000185270.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Schneider, L. S., i J. T. Olin. "Overview of Clinical Trials of Hydergine in Dementia". Archives of Neurology 51, nr 8 (1.08.1994): 787–98. http://dx.doi.org/10.1001/archneur.1994.00540200063018.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Kuskowski, Michael A., Gerald Morley, Stephen M. Malone, Maurice W. Dysken i Amy Okaya. "Hydergine Treatment and Psychophysiological Measures in Primary Degenerative Dementia". Journal of Geriatric Psychiatry and Neurology 3, nr 1 (styczeń 1990): 41–47. http://dx.doi.org/10.1177/089198879000300109.

Pełny tekst źródła

Streszczenie:

Changes in smooth pursuit eye movements and the P300 component of the auditory evoked potential were studied in patients with primary degenerative dementia during a double-blind, placebo-controlled study of ergoloid mesylates (Hydergine). After 18 weeks of treatment, P300 latency and amplitude, recorded at three scalp electrode sites, had not changed significantly. Smooth pursuit gain was elevated for the drug group under some stimulus conditions, suggesting a normalization of pursuit eye movement functioning. However, the results of several other measures of the quality of pursuit eye movements failed to corroborate this finding. ( J Geriatr Psychiatry Neurol 1990; 3:41-47).

Style APA, Harvard, Vancouver, ISO itp.

9

Sobky, A. El, M. El Shazly, A. K. Darwish, T. Davies, K. Griffin i M. S. Keshavan. "Hydergine effect on prolactin and reaction time in dementia". Biological Psychiatry 21, nr 12 (październik 1986): 1229–30. http://dx.doi.org/10.1016/0006-3223(86)90230-1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Lon, S., M. D. Schneider, T. Jason i A. M. Olin. "Meta-analysis of hydergine clinical trials in primary dementia". Neurobiology of Aging 13 (styczeń 1992): S123. http://dx.doi.org/10.1016/0197-4580(92)90613-3.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

TAKEHARA, KAZUHIKO. "Clinical usefulness of hydergine tablets for Raynaud phenomenon in scleroderma." Nishi Nihon Hifuka 58, nr 5 (1996): 840–42. http://dx.doi.org/10.2336/nishinihonhifu.58.840.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

BECHGAARD, POUL, i LEIF PAULSEN. "Dihydrogenated Ergot Alkaloids (Hydergine) in the Treatment of Essential Hypertension." Acta Medica Scandinavica 145, nr 3 (24.04.2009): 189–99. http://dx.doi.org/10.1111/j.0954-6820.1953.tb07010.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Rodriguez, D. V., D. F. Peeler, R. R. Smith, T. S. Sanders i J. B. Beckett. "ATTENUATION OF ISCHEMIA-REPERFUSION INJURY IN GERBIL HIPPOCAMPUS BY HYDERGINE". Southern Medical Journal 84, Supplement (wrzesień 1991): 42. http://dx.doi.org/10.1097/00007611-199109001-00143.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Datta, Kapal D., Richard C. Evenson, Patrick J. Gannon i Earl P. Dick. "Efficacy of oral hydergine (ergoloid mesylates) in alcohol related encephalopathy". Progress in Neuro-Psychopharmacology and Biological Psychiatry 11, nr 1 (styczeń 1987): 87–90. http://dx.doi.org/10.1016/0278-5846(87)90035-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Thompson, Troy L., Christopher M. Filley, Wayne D. Mitchell, Kathleen M. Culig, Mary LoVerde i Richard L. Byyny. "Lack of Efficacy of Hydergine in Patients with Alzheimer's Disease". New England Journal of Medicine 323, nr 7 (16.08.1990): 445–48. http://dx.doi.org/10.1056/nejm199008163230704.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Harirî, N., B. Falakal i O. Algan. "THE EFFECTS OF HYDERGINE ON THE SYNAPTIC PLASTICITY OF AGED RATS". Clinical Neuropharmacology 15 (1992): 560B. http://dx.doi.org/10.1097/00002826-199202001-01093.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Qizilbash, Nawab. "The Cochrane Dementia and Cognitive Impairment Group". Reviews in Clinical Gerontology 7, nr 2 (luty 1997): 183–88. http://dx.doi.org/10.1017/s0959259897000208.

Pełny tekst źródła

Streszczenie:

Over 2000 randomized trials are reported in the literature for the treatment of dementia and cognitive decline. Yet the responses to the question, ‘Which treatments are effective in dementia?’ are likely to be various and conflicting. Wide variation in practice exists, and for drug therapy, where information is more readily available, different treatments are used in different countries. For example, only one drug (Hydergine) is licensed in the UK for dementia, though rarely used, while there are over 30 drugs in use in Japan for dementia and cognitive decline, five in Spain, and two in the USA. This inconsistency is likely to be even greater for interventions of psychological and behavioural therapies, environmental therapy and the organization of care.

Style APA, Harvard, Vancouver, ISO itp.

18

PÖLDRE, ARVO. "Two-Year Results of Hydergine Therapy in Hypertension and Other Circulatory Disturbances". Acta Medica Scandinavica 155, nr 6 (24.04.2009): 437–48. http://dx.doi.org/10.1111/j.0954-6820.1956.tb14392.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

ROTHLIN, E., A. CERLETTI i H. EMMENEGGER. "Experimental Psycho-neurogenic Hypertension and its Treatment with Hydrogenated Ergot Alkaloids (Hydergine)". Acta Medica Scandinavica 154, S312 (24.04.2009): 27–35. http://dx.doi.org/10.1111/j.0954-6820.1956.tb16947.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Sunderland, T., K. T. Putnam, R. Martinez, A. Mellow, B. A. Lawlor, B. Vitiello, S. Molchan, R. M. Cohen i H. Weingartner. "COGNITIVE EFFECTS OF LONG-TERM DEPRENYL AND HYDERGINE IN ALZHEIMERʼS DISEASE PATIENTS". Clinical Neuropharmacology 15 (1992): 161B. http://dx.doi.org/10.1097/00002826-199202001-00310.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

lmperato, Assunta, Maria Carmen Obinu, Laura Dazzi, Giovanna Carta, Maria Stefania Mascia, Maria Antonietta Casu i Gian Luigi Gessa. "Co-dergocrine (Hydergine) regulates striatal and hippocampal acetylcholine release through D2 receptors". NeuroReport 5, nr 6 (luty 1994): 674–76. http://dx.doi.org/10.1097/00001756-199402000-00003.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Kitaoku, Yoshiyuki, Takashi Matsunaga i Hiroyuki Kitamura. "Clinical Study of Ternelin Therapy and Ternelin and Hydergine Therapy for Tinnitus." Practica Oto-Rhino-Laryngologica 88, nr 5 (1995): 645–56. http://dx.doi.org/10.5631/jibirin.88.645.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Ehrly, A. M., i K. Saeger-Lorenz. "The effect of Hydergine® on the filterability of erythrocytes from hyperosmolar blood". Clinical Hemorheology and Microcirculation 12, nr 2 (1992): 223–28. http://dx.doi.org/10.3233/ch-1992-12207.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

SINGH, S. K., J. N. M. IJZERMANS, R. L. MARQUET, R. W. F. DE BRUIN, D. L. WESTBROEK i J. JEEKEL. "EFFECT OF HYDERGINE ON CYCLOSPORINE-INDUCED NEPHROTOXICITY IN A RAT KIDNEY TRANSPLANTATION MODEL". Transplantation 43, nr 4 (kwiecień 1987): 593–94. http://dx.doi.org/10.1097/00007890-198704000-00033.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

KAPPERT, ARNOLD, CARL-HENRIK SKOGLUND, ANDERS BERGHOLTZ i GUSTAV NYLIN. "The Effect of Hydergine (CCK) on Reflex Vasoconstriction and Reflex Blood Pressure Stimulation". Acta Medica Scandinavica 141, nr 6 (24.04.2009): 440–50. http://dx.doi.org/10.1111/j.0954-6820.1952.tb14234.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Werneke, Ursula, Trevor Turner i Stefan Priebe. "Complementary medicines in psychiatry". British Journal of Psychiatry 188, nr 2 (luty 2006): 109–21. http://dx.doi.org/10.1192/bjp.188.2.109.

Pełny tekst źródła

Streszczenie:

BackgroundThe use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed.AimsTo review the complementary medicines routinely encountered in psychiatric practice, their effectiveness, potential adverse effects and interactions.MethodElectronic and manual literature search on the effectiveness and safety of psychotropic complementary medicines.ResultsPotentially useful substances include ginkgo and hydergine as cognitive enhancers, passion flower and valerian as sedatives, St John's wort and sadenosylmethionine as antidepressants, and selenium and folate to complement antidepressants. The evidence is less conclusive for the use of omega-3 fatty acids as augmentation treatment in schizophrenia, melatonin for tardive dyskinesia and 18-methoxycoronaridine, an ibogaine derivative, for the treatment of cocaine and heroin addiction.ConclusionsSystematic clinical trials are needed to test promising substances. Meanwhile, those wishing to take psychotropic complementary medicines require appropriate advice.

Style APA, Harvard, Vancouver, ISO itp.

27

Izumiyama, K., i K. Kogure. "Effect of dihydroergotoxine mesylate (Hydergine®) on delayed neuronal death in the gerbil hippocampus". Acta Neurologica Scandinavica 78, nr 3 (wrzesień 1988): 214–20. http://dx.doi.org/10.1111/j.1600-0404.1988.tb03649.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

Huber, F., S. Köberle, H. Prestele i R. Spiegel. "Effects of long-term ergoloid mesylates (‘Hydergine’) administration in healthy pensioners: 5-year results". Current Medical Research and Opinion 10, nr 4 (styczeń 1986): 256–79. http://dx.doi.org/10.1185/03007998609110447.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

Amenta, Daniela, Fabio Ferrante, Flavio Franch i Francesco Amenta. "Effects of Long-Term Hydergine® Administration on Lipofuscin Accumulation in Senescent Rat Brain". Gerontology 34, nr 5-6 (1988): 250–56. http://dx.doi.org/10.1159/000212963.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Steurer, G., P. Fitscha, K. Ettl i H. Sinzinger. "Effects of hydergine on platelet deposition on “active” human carotid artery lesions and platelet function". Thrombosis Research 55, nr 5 (wrzesień 1989): 577–89. http://dx.doi.org/10.1016/0049-3848(89)90390-3.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

Boulat, O., P. Waldmeier i L. Maitre. "3,4-Dihydroxyphenylacetic acid (DOPAC) as an index of noradrenaline turnover: Effects of hydergine� and vincamine". Journal of Neural Transmission 82, nr 3 (październik 1990): 181–95. http://dx.doi.org/10.1007/bf01272761.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Hariri, N. I., A. Büyüköztürk, L. Kanit, B. Ersöz i G. Menteş. "The effects of hydergine on the MAO activity of the aged and adult rat brain". European Neuropsychopharmacology 4, nr 3 (wrzesień 1994): 399–400. http://dx.doi.org/10.1016/0924-977x(94)90231-3.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

Büyüköztürk, As'lihan, Lütfiye Kanıt, Biltan Ersöz, Gülriz Menteş i Nuran İ. Hariri. "The effects of hydergine on the MAO activity of the aged and adult rat brain". European Neuropsychopharmacology 5, nr 4 (grudzień 1995): 527–29. http://dx.doi.org/10.1016/0924-977x(95)80014-s.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

NAGASAWA, HARUO, KYUYA KOGURE, KOICHIRO KAWASHIMA, TATSUO IDO, MASATOSHI ITOH i JUN HATAZAWA. "Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography." Tohoku Journal of Experimental Medicine 162, nr 3 (1990): 225–33. http://dx.doi.org/10.1620/tjem.162.225.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Ammon, Ronald, Rehka Sharma, Steven R. Gambert i Krishan Lal Gupta. "Hydergine revisited: A statistical analysis of studies showing efficacy in the treatment of cognitively impaired elderly". AGE 18, nr 1 (styczeń 1995): 5–9. http://dx.doi.org/10.1007/bf02434076.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

Bullock, R. "Review: hydergine leads to greater global improvement and greater improvement on comprehensive rating scales in dementia". Evidence-Based Mental Health 2, nr 1 (1.02.1999): 15. http://dx.doi.org/10.1136/ebmh.2.1.15.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Shoptaw, Steven, Donnie W. Watson, Chris Reiber, Richard A. Rawson, Margaret A. Montgomery, Maria D. Majewska i Walter Ling. "Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)". Addiction 100 (marzec 2005): 78–90. http://dx.doi.org/10.1111/j.1360-0443.2005.00991.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Orma, H., i S. Vannas. "OBSERVATIONS ON THE USE OF PH 203 AND HYDERGINE IN SOME CIRCULATORY DISTURBANCES OF THE FUNDUS AND VASCULAR RETINOPATHY". Acta Ophthalmologica 36, nr 4 (27.05.2009): 734–49. http://dx.doi.org/10.1111/j.1755-3768.1958.tb02284.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Meier-Ruge, W. "Effects of prolonged co-dergocrine mesylate (Hydergine®) treatment on local cerebral glucose uptake in aged Fischer 344 rats". Archives of Gerontology and Geriatrics 5, nr 1 (kwiecień 1986): 65–77. http://dx.doi.org/10.1016/0167-4943(86)90009-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

Bertoni-Freddari, C., C. Giuli, C. Pieri, D. Paci, L. Amadio, M. Ermini i A. Dravid. "The Effect of Chronic Hydergine Treatment on the Plasticity of Synaptic Junctions in the Dentate Gyms of Aged Rats". Journal of Gerontology 42, nr 5 (1.09.1987): 482–86. http://dx.doi.org/10.1093/geronj/42.5.482.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Rouy, L. M., A. M. Douillon, R. Compan i Y. Wolmark. "Ergoloid mesylates ('Hydergine') in the treatment of mental deterioration in the elderly: A 6-month double-blind, placebo-controlled trial". Current Medical Research and Opinion 11, nr 6 (styczeń 1989): 380–89. http://dx.doi.org/10.1185/03007998909110139.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Serino, Anthony, Kwai Kan, Kimberly Graves, Christopher Kule i Adam Anthony. "Age, strain, and semi-chronic hydergine treatment effects on motor activity and neuronal nucleic acid-protein metabolism in male mice". Life Sciences 67, nr 12 (sierpień 2000): 1489–505. http://dx.doi.org/10.1016/s0024-3205(00)00732-3.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Hochberg, Ingrid. "MORPHOLOGICAL STUDIES ON THE EFFECT OF HYDERGINE ON THE ANTERIOR HORN CELLS AND THE CELLS OF NUCLEI VII, X, AND XII". Acta Pathologica Microbiologica Scandinavica 32, nr 2 (18.08.2009): 300–315. http://dx.doi.org/10.1111/j.1699-0463.1953.tb00255.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Schoups, A. A., V. K. Saxena, K. Tombeur i W. P. De Potter. "Facilitation of the release of noradrenaline and neuropeptide Y by the α2-adrenoceptor blocking agents idazoxan and hydergine in the dog spleen". Life Sciences 42, nr 5 (styczeń 1988): 517–23. http://dx.doi.org/10.1016/0024-3205(88)90092-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Amenta, Francesco, Anne-Lise Jaton i Alberto Ricci. "Effect of long term hydergine treatment on the age-dependent loss of mossy fibers and of granule cells in the rat hippocampus". Archives of Gerontology and Geriatrics 10, nr 3 (maj 1990): 287–96. http://dx.doi.org/10.1016/0167-4943(90)90030-a.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Saletu, B., J. Grünberger, P. Anderer, L. Linzmayer, G. Pakesch i G. Zyhlarz. "Effect-kinetics on brain protection of two codergocrine-mesylate preparations (Aramexe retard® and Hydergine®) by EEG mapping and psychometry under hypoxia". Archives of Gerontology and Geriatrics 18, nr 2 (marzec 1994): 81–99. http://dx.doi.org/10.1016/0167-4943(94)00533-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Arrigo, A., R. Casale, I. Giorgi, C. Guarnaschelli i F. Zelaschi. "Effects of Intravenous High Dose Co-Dergocrine Mesylate (‘Hydergine’®) in Elderly Patients with Severe Multi-Infarct Dementia: a Double-Blind, Placebo-Controlled Trial". Current Medical Research and Opinion 11, nr 8 (styczeń 1989): 491–500. http://dx.doi.org/10.1185/03007998909110460.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Unseld, H. "Vasospasmus nach Leberruptur, Dopamin- und Hydergin®-Infusion". AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie 20, nr 06 (grudzień 1985): 339–41. http://dx.doi.org/10.1055/s-2007-1003135.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Gripwall, E., i A. Pöldre. "Einige Erfahrungen aus der Behandlung von essentieller Hypertonie mit Hydergin". Acta Medica Scandinavica 154, S312 (24.04.2009): 245–47. http://dx.doi.org/10.1111/j.0954-6820.1956.tb16991.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Thienhaus, Ole J., Beverly G. Wheeler, Sandra Simon, Frank P. Zemlan i James T. Hartford. "A Controlled Double-Blind Study of High-Dose Dihydroergotoxine Mesylate (HydergineR) in Mild Dementia". Journal of the American Geriatrics Society 35, nr 3 (marzec 1987): 219–23. http://dx.doi.org/10.1111/j.1532-5415.1987.tb02312.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!